Baidu
map

感染检验什么好?HBP、PCT、还是CRP?

2017-09-17 花春兰 检验视界网

感染性疾病是临床常见的威胁健康的疾病,常用的指标有降钙素原、C-反应蛋白、白细胞计数、血沉、IL-6等,他们的定义是什么,他们的区别又是什么?

导语

感染性疾病是临床常见的威胁健康的疾病,常用的指标有降钙素原、C-反应蛋白、白细胞计数、血沉、IL-6等,他们的定义是什么,他们的区别又是什么?

肝素结合蛋白

肝素结合蛋白(heparin-bindingprotein,HBP):是中性粒细胞来源的颗粒蛋白,其结构包含222个氨基酸的单链蛋白,含有8个半胱氨酸残基,在第100、114或145位天冬氨酸残基上具有糖基化位点,结构类似于中性粒细胞弹性蛋白,与其同源性为45%。

HBP在临床上的应用:HBP主要是由PMN受外界刺激所释放,所以正常人血中HBP含量很低,一般不超过10ng/ml,当有感染发生时,部分细菌侵入到血管内,菌体本身或者细菌释放的毒素等物质刺激中细粒细包释放HBP从而导致血中HBP含量升高,HBP在一般感染时能达到20-30ng/ml,ICU中严重感染会更高,可能超过100ng/ml。

1)HBP作为局部感染的诊断指标:当脑脊液HBP水平超过20ng/ml时,诊断急性细菌性脑膜炎可以达到100%的敏感性和99.2%的特异性以及96.2%的阳性预测值和100%的阴性预测值,因此脑脊液中HBP水平可以提高区分细菌性和病毒性神经系统感染的准确性。

2)HBP辅助诊断尿道感染:U-HBP作为判断尿路感染的敏感性和特异性分别是93.3%和90.3%,同时阴性预测值也达到98.3%,但U-HBP的阳性预测值不太理想,只能达到70%与亚硝酸盐结合起来将是一个很好的生化指标。

3)HBP对感染性休克发生的预测:对比健康人对照组和患者包括尿路感染、肺炎、肠胃炎等局部感染但没有伴休克的患者血清中HBP水平,发现组间HBP水平并没有显著差异,而患有非脓毒性休克和脓毒性休克患者之间血清HBP水平却没有显著差异,因此发生感染的病人血中HBP水平不一定显著升高,但发生休克的病人HBP水平一定会显著升高,造成这一现象发生的原因与HBP改变血管通透性密不可分。

4)HBP对败血症中循环衰竭的预测:对伴休克的严重败血症、未伴休克的严重败血症、败血症、感染但未伴全身炎症反应综合征、全身炎症反应综合征但未发生感染这5组血液中HBP、PCT、IL-6、CRP水平以及WBC研究发现,伴休克的严重败血症病人HBP水平显著高于未伴休克的严重败血症病人,同时这两组病人HBP水平显著高于其他三组病人。目前临床上将HBP作为严重败血症的标志,其敏感性、特异性、阳性预测值和阴性预测值分别可以达到87.1%、95.1%、88.4%以及94.5%。

降钙素原

降钙素原(procalcitonin,PCT):血清降钙素(CT)的前肽物质,由甲状腺C细胞分泌产生,是由116个氨基酸组成的无激素活性糖蛋白质,含量极少,在健康人群的血清或脑脊液中几乎不能被检出。

PCT在临床上的应用:细菌感染、真菌感染及寄生虫感染时水平升高,并且增高的程度与感染的严重程度及预后相关;无菌性炎症和病毒感染时无升高或者轻微升高。因此,PCT水平的监测在全身性细菌感染和脓毒症辅助鉴别诊断、预后判断、疗效观察等方面有很高的临床价值。

1)用于脓毒症的诊断和鉴别诊断:《降钙素原PCT急诊临床应用的专家共识》指出:PCT在SIRS/脓毒症、严重脓毒症和脓毒症休克患者的质量浓度依次增高,与病情的严重度呈正相关。脓毒症患者的PCT水平明显高于非脓毒症患者,高水平PCT表明全身炎症反应非常严重,死亡风险很高,应立即开始抗生素及针对性治疗。另外,PCT升高对细菌感染导致的脓毒症特异性很高,可作为诊断脓毒症和鉴别严重细菌感染的生物标志物。

2)细菌感染与病毒感染的鉴别诊断:细菌感染、真菌感染及寄生虫感染时水平才会升高,但病毒感染时无升高或者轻微升高,因此,PCT鉴别病毒性疾病的敏感度和特异性均高于传统标记物(如IL-6、白细胞)。

3)大手术和严重创伤患者细菌感染并发症监测:严重创伤和手术时血浆PCT浓度通常可能会轻微的升高,但很快会下降,若术后血浆PCT则一直保持高水平或持续升高,则可能是术后或伤后并发细菌感染,需要考虑使用抗生素控制感染。

C-反应蛋白

C-反应蛋白(CRP):是机体在应激状态下由肝脏合成的急性时相反应蛋白,分子量为105kD,包含五个相同的多肽链亚单位。其合成主要受IL-1、IL-6和TNF-α及糖皮质激素的调控,正常情况下血浆中的含量低,在机体的抗感染防御及炎症过程中起着重要作用。

CRP在临床上的应用:比较敏感的感染急相反应蛋白,在健康的正常人体中CRP含量极微,浓度最高为5mg/L。感染急性期CRP浓度快速升高,其升高常先于发烧等临床症状出现,在6-12小时内开始上升,并在24-48小时内达到高峰,其升高的幅度与感染的程度呈正相关。

1)监控病情变化及抗生素疗效观察:CRP在血中升高的幅度与感染的程度正相关。对与用抗生素治疗细菌感染时,动态检测血清中CRP水平是必要的,可以作为抗生素治疗是否有效的判定,在粒细胞缺乏症或机体免疫状态抑制时更有临床意义。

2)鉴别细菌感染与病毒感染:细菌感染、真菌感染及寄生虫感染时水平才会升高,但病毒感染时无升高或者轻微升高,因此,除了一些严重侵袭导致组织损伤的病毒如腺病毒、疱疹病毒等外,CRP可用来鉴别病毒感染与细菌感染。

3)预测心血管病危险:急性心肌梗死时CRP升高,CRP可作为缺血性中风预后的独立预报指标。持续的轻度CRP升高,可用来预测动脉粥样硬化的发生。

HBP、PCT、CRP的比较

HBP:灵敏度高、特异性强、阳性/阴性检出率高,感染早期即可检测出,在急性细菌性感染时浓度高,而在病毒感染和非特异性炎症时浓度低。

PCT:感染早期即可出现,在机体感染产生全身反应时升高,在局部感染和慢性感染时血清水平升高不明显。

CRP:多种感染及非感染因素(手术)均可以起CRP升高,在感染发生后6-8h开始升高,24-48h达到高峰,特异性不理想。

感染性疾病是临床常见的威胁健康的疾病,常用的指标有降钙素原、C-反应蛋白、白细胞计数、血沉、IL-6等,但如何及早合理的选择检测指标需要临床医生根据患者的本身情况来选择。

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (10)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1924723, encodeId=357e1924e2325, content=<a href='/topic/show?id=4fd31388ecf' target=_blank style='color:#2F92EE;'>#PCT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13887, encryptionId=4fd31388ecf, topicName=PCT)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=796422, createdName=lvliquan, createdTime=Fri Oct 06 19:13:00 CST 2017, time=2017-10-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1269594, encodeId=6cce126959415, content=<a href='/topic/show?id=ca6952e52f' target=_blank style='color:#2F92EE;'>#CRP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5275, encryptionId=ca6952e52f, topicName=CRP)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Tue Sep 19 06:13:00 CST 2017, time=2017-09-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=245356, encodeId=5bdf245356e4, content=学习一下新知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=114, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/syBKejEucZo9aZXqKib7wdZYRpZOzeEKDyA59Er4fkK2ff1X7w9pfDTWUY75EBCpsNo0iaGqly7sJMtEPI2Pur6Q/0, createdBy=eb672097339, createdName=lucycici, createdTime=Mon Sep 18 16:43:25 CST 2017, time=2017-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=245341, encodeId=95f42453415d, content=学习.谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyhb9xDeHojCicsdRdyC3XXdGk2ib9yLypZuHN06WeW4HO8WN0GGrgEfvnTX8gsckof05GHOU5OM4Mvx/0, createdBy=9cee1982656, createdName=执着追梦, createdTime=Mon Sep 18 14:17:39 CST 2017, time=2017-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=245192, encodeId=64b7245192a9, content=是, beContent=null, objectType=article, channel=null, level=null, likeNumber=108, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6lR0HdZibhWZ6rWAh3YccOK4EzafUdF0qLoia0v0xMic7vVJosqww22ib6RPRNBMS6ZMP4UvsoiaawAhtW1E5FNJvcK/0, createdBy=ac701981244, createdName=1e182ff9m99(暂无匿称), createdTime=Mon Sep 18 06:31:06 CST 2017, time=2017-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=245150, encodeId=744724515067, content=谢谢分享.感觉收获很大, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160914/IMG57D82E721DB581755.jpg, createdBy=4fc81933929, createdName=明天会更好!, createdTime=Mon Sep 18 00:11:40 CST 2017, time=2017-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=245097, encodeId=a86324509eca, content=谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=114, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTL8GV06roPeF96gmNNe5qicpI81qEbXLy1oKu8HDafssvuSfccR9UQIFkFFESxJ0ECOjgVoAt6QlaQ/132, createdBy=50201623070, createdName=wylj, createdTime=Sun Sep 17 22:12:32 CST 2017, time=2017-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=245053, encodeId=3fd3245053b0, content=学习了.感谢分享., beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=60791943465, createdName=1e0f8808m18(暂无匿称), createdTime=Sun Sep 17 17:08:59 CST 2017, time=2017-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=245046, encodeId=e7f5245046a2, content=学习了.谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3zSn0GqHrsfLGSUSR8zwnWWLT4FMl5XH8S58HuZslVkLsAPbXDXaliagK7TOxQfmngKibG1yrDonepCLDkcxGk8hS/0, createdBy=b8282062892, createdName=changjiu, createdTime=Sun Sep 17 16:42:01 CST 2017, time=2017-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=245041, encodeId=52c924504147, content=目前仍然C反应蛋白为核心, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=lovetcm, createdTime=Sun Sep 17 15:36:51 CST 2017, time=2017-09-17, status=1, ipAttribution=)]
    2017-10-06 lvliquan
  2. [GetPortalCommentsPageByObjectIdResponse(id=1924723, encodeId=357e1924e2325, content=<a href='/topic/show?id=4fd31388ecf' target=_blank style='color:#2F92EE;'>#PCT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13887, encryptionId=4fd31388ecf, topicName=PCT)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=796422, createdName=lvliquan, createdTime=Fri Oct 06 19:13:00 CST 2017, time=2017-10-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1269594, encodeId=6cce126959415, content=<a href='/topic/show?id=ca6952e52f' target=_blank style='color:#2F92EE;'>#CRP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5275, encryptionId=ca6952e52f, topicName=CRP)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Tue Sep 19 06:13:00 CST 2017, time=2017-09-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=245356, encodeId=5bdf245356e4, content=学习一下新知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=114, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/syBKejEucZo9aZXqKib7wdZYRpZOzeEKDyA59Er4fkK2ff1X7w9pfDTWUY75EBCpsNo0iaGqly7sJMtEPI2Pur6Q/0, createdBy=eb672097339, createdName=lucycici, createdTime=Mon Sep 18 16:43:25 CST 2017, time=2017-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=245341, encodeId=95f42453415d, content=学习.谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyhb9xDeHojCicsdRdyC3XXdGk2ib9yLypZuHN06WeW4HO8WN0GGrgEfvnTX8gsckof05GHOU5OM4Mvx/0, createdBy=9cee1982656, createdName=执着追梦, createdTime=Mon Sep 18 14:17:39 CST 2017, time=2017-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=245192, encodeId=64b7245192a9, content=是, beContent=null, objectType=article, channel=null, level=null, likeNumber=108, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6lR0HdZibhWZ6rWAh3YccOK4EzafUdF0qLoia0v0xMic7vVJosqww22ib6RPRNBMS6ZMP4UvsoiaawAhtW1E5FNJvcK/0, createdBy=ac701981244, createdName=1e182ff9m99(暂无匿称), createdTime=Mon Sep 18 06:31:06 CST 2017, time=2017-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=245150, encodeId=744724515067, content=谢谢分享.感觉收获很大, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160914/IMG57D82E721DB581755.jpg, createdBy=4fc81933929, createdName=明天会更好!, createdTime=Mon Sep 18 00:11:40 CST 2017, time=2017-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=245097, encodeId=a86324509eca, content=谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=114, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTL8GV06roPeF96gmNNe5qicpI81qEbXLy1oKu8HDafssvuSfccR9UQIFkFFESxJ0ECOjgVoAt6QlaQ/132, createdBy=50201623070, createdName=wylj, createdTime=Sun Sep 17 22:12:32 CST 2017, time=2017-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=245053, encodeId=3fd3245053b0, content=学习了.感谢分享., beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=60791943465, createdName=1e0f8808m18(暂无匿称), createdTime=Sun Sep 17 17:08:59 CST 2017, time=2017-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=245046, encodeId=e7f5245046a2, content=学习了.谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3zSn0GqHrsfLGSUSR8zwnWWLT4FMl5XH8S58HuZslVkLsAPbXDXaliagK7TOxQfmngKibG1yrDonepCLDkcxGk8hS/0, createdBy=b8282062892, createdName=changjiu, createdTime=Sun Sep 17 16:42:01 CST 2017, time=2017-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=245041, encodeId=52c924504147, content=目前仍然C反应蛋白为核心, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=lovetcm, createdTime=Sun Sep 17 15:36:51 CST 2017, time=2017-09-17, status=1, ipAttribution=)]
    2017-09-19 智智灵药
  3. [GetPortalCommentsPageByObjectIdResponse(id=1924723, encodeId=357e1924e2325, content=<a href='/topic/show?id=4fd31388ecf' target=_blank style='color:#2F92EE;'>#PCT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13887, encryptionId=4fd31388ecf, topicName=PCT)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=796422, createdName=lvliquan, createdTime=Fri Oct 06 19:13:00 CST 2017, time=2017-10-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1269594, encodeId=6cce126959415, content=<a href='/topic/show?id=ca6952e52f' target=_blank style='color:#2F92EE;'>#CRP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5275, encryptionId=ca6952e52f, topicName=CRP)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Tue Sep 19 06:13:00 CST 2017, time=2017-09-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=245356, encodeId=5bdf245356e4, content=学习一下新知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=114, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/syBKejEucZo9aZXqKib7wdZYRpZOzeEKDyA59Er4fkK2ff1X7w9pfDTWUY75EBCpsNo0iaGqly7sJMtEPI2Pur6Q/0, createdBy=eb672097339, createdName=lucycici, createdTime=Mon Sep 18 16:43:25 CST 2017, time=2017-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=245341, encodeId=95f42453415d, content=学习.谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyhb9xDeHojCicsdRdyC3XXdGk2ib9yLypZuHN06WeW4HO8WN0GGrgEfvnTX8gsckof05GHOU5OM4Mvx/0, createdBy=9cee1982656, createdName=执着追梦, createdTime=Mon Sep 18 14:17:39 CST 2017, time=2017-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=245192, encodeId=64b7245192a9, content=是, beContent=null, objectType=article, channel=null, level=null, likeNumber=108, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6lR0HdZibhWZ6rWAh3YccOK4EzafUdF0qLoia0v0xMic7vVJosqww22ib6RPRNBMS6ZMP4UvsoiaawAhtW1E5FNJvcK/0, createdBy=ac701981244, createdName=1e182ff9m99(暂无匿称), createdTime=Mon Sep 18 06:31:06 CST 2017, time=2017-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=245150, encodeId=744724515067, content=谢谢分享.感觉收获很大, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160914/IMG57D82E721DB581755.jpg, createdBy=4fc81933929, createdName=明天会更好!, createdTime=Mon Sep 18 00:11:40 CST 2017, time=2017-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=245097, encodeId=a86324509eca, content=谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=114, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTL8GV06roPeF96gmNNe5qicpI81qEbXLy1oKu8HDafssvuSfccR9UQIFkFFESxJ0ECOjgVoAt6QlaQ/132, createdBy=50201623070, createdName=wylj, createdTime=Sun Sep 17 22:12:32 CST 2017, time=2017-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=245053, encodeId=3fd3245053b0, content=学习了.感谢分享., beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=60791943465, createdName=1e0f8808m18(暂无匿称), createdTime=Sun Sep 17 17:08:59 CST 2017, time=2017-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=245046, encodeId=e7f5245046a2, content=学习了.谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3zSn0GqHrsfLGSUSR8zwnWWLT4FMl5XH8S58HuZslVkLsAPbXDXaliagK7TOxQfmngKibG1yrDonepCLDkcxGk8hS/0, createdBy=b8282062892, createdName=changjiu, createdTime=Sun Sep 17 16:42:01 CST 2017, time=2017-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=245041, encodeId=52c924504147, content=目前仍然C反应蛋白为核心, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=lovetcm, createdTime=Sun Sep 17 15:36:51 CST 2017, time=2017-09-17, status=1, ipAttribution=)]
    2017-09-18 lucycici

    学习一下新知识

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1924723, encodeId=357e1924e2325, content=<a href='/topic/show?id=4fd31388ecf' target=_blank style='color:#2F92EE;'>#PCT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13887, encryptionId=4fd31388ecf, topicName=PCT)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=796422, createdName=lvliquan, createdTime=Fri Oct 06 19:13:00 CST 2017, time=2017-10-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1269594, encodeId=6cce126959415, content=<a href='/topic/show?id=ca6952e52f' target=_blank style='color:#2F92EE;'>#CRP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5275, encryptionId=ca6952e52f, topicName=CRP)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Tue Sep 19 06:13:00 CST 2017, time=2017-09-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=245356, encodeId=5bdf245356e4, content=学习一下新知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=114, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/syBKejEucZo9aZXqKib7wdZYRpZOzeEKDyA59Er4fkK2ff1X7w9pfDTWUY75EBCpsNo0iaGqly7sJMtEPI2Pur6Q/0, createdBy=eb672097339, createdName=lucycici, createdTime=Mon Sep 18 16:43:25 CST 2017, time=2017-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=245341, encodeId=95f42453415d, content=学习.谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyhb9xDeHojCicsdRdyC3XXdGk2ib9yLypZuHN06WeW4HO8WN0GGrgEfvnTX8gsckof05GHOU5OM4Mvx/0, createdBy=9cee1982656, createdName=执着追梦, createdTime=Mon Sep 18 14:17:39 CST 2017, time=2017-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=245192, encodeId=64b7245192a9, content=是, beContent=null, objectType=article, channel=null, level=null, likeNumber=108, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6lR0HdZibhWZ6rWAh3YccOK4EzafUdF0qLoia0v0xMic7vVJosqww22ib6RPRNBMS6ZMP4UvsoiaawAhtW1E5FNJvcK/0, createdBy=ac701981244, createdName=1e182ff9m99(暂无匿称), createdTime=Mon Sep 18 06:31:06 CST 2017, time=2017-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=245150, encodeId=744724515067, content=谢谢分享.感觉收获很大, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160914/IMG57D82E721DB581755.jpg, createdBy=4fc81933929, createdName=明天会更好!, createdTime=Mon Sep 18 00:11:40 CST 2017, time=2017-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=245097, encodeId=a86324509eca, content=谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=114, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTL8GV06roPeF96gmNNe5qicpI81qEbXLy1oKu8HDafssvuSfccR9UQIFkFFESxJ0ECOjgVoAt6QlaQ/132, createdBy=50201623070, createdName=wylj, createdTime=Sun Sep 17 22:12:32 CST 2017, time=2017-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=245053, encodeId=3fd3245053b0, content=学习了.感谢分享., beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=60791943465, createdName=1e0f8808m18(暂无匿称), createdTime=Sun Sep 17 17:08:59 CST 2017, time=2017-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=245046, encodeId=e7f5245046a2, content=学习了.谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3zSn0GqHrsfLGSUSR8zwnWWLT4FMl5XH8S58HuZslVkLsAPbXDXaliagK7TOxQfmngKibG1yrDonepCLDkcxGk8hS/0, createdBy=b8282062892, createdName=changjiu, createdTime=Sun Sep 17 16:42:01 CST 2017, time=2017-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=245041, encodeId=52c924504147, content=目前仍然C反应蛋白为核心, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=lovetcm, createdTime=Sun Sep 17 15:36:51 CST 2017, time=2017-09-17, status=1, ipAttribution=)]
    2017-09-18 执着追梦

    学习.谢谢分享

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1924723, encodeId=357e1924e2325, content=<a href='/topic/show?id=4fd31388ecf' target=_blank style='color:#2F92EE;'>#PCT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13887, encryptionId=4fd31388ecf, topicName=PCT)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=796422, createdName=lvliquan, createdTime=Fri Oct 06 19:13:00 CST 2017, time=2017-10-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1269594, encodeId=6cce126959415, content=<a href='/topic/show?id=ca6952e52f' target=_blank style='color:#2F92EE;'>#CRP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5275, encryptionId=ca6952e52f, topicName=CRP)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Tue Sep 19 06:13:00 CST 2017, time=2017-09-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=245356, encodeId=5bdf245356e4, content=学习一下新知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=114, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/syBKejEucZo9aZXqKib7wdZYRpZOzeEKDyA59Er4fkK2ff1X7w9pfDTWUY75EBCpsNo0iaGqly7sJMtEPI2Pur6Q/0, createdBy=eb672097339, createdName=lucycici, createdTime=Mon Sep 18 16:43:25 CST 2017, time=2017-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=245341, encodeId=95f42453415d, content=学习.谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyhb9xDeHojCicsdRdyC3XXdGk2ib9yLypZuHN06WeW4HO8WN0GGrgEfvnTX8gsckof05GHOU5OM4Mvx/0, createdBy=9cee1982656, createdName=执着追梦, createdTime=Mon Sep 18 14:17:39 CST 2017, time=2017-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=245192, encodeId=64b7245192a9, content=是, beContent=null, objectType=article, channel=null, level=null, likeNumber=108, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6lR0HdZibhWZ6rWAh3YccOK4EzafUdF0qLoia0v0xMic7vVJosqww22ib6RPRNBMS6ZMP4UvsoiaawAhtW1E5FNJvcK/0, createdBy=ac701981244, createdName=1e182ff9m99(暂无匿称), createdTime=Mon Sep 18 06:31:06 CST 2017, time=2017-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=245150, encodeId=744724515067, content=谢谢分享.感觉收获很大, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160914/IMG57D82E721DB581755.jpg, createdBy=4fc81933929, createdName=明天会更好!, createdTime=Mon Sep 18 00:11:40 CST 2017, time=2017-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=245097, encodeId=a86324509eca, content=谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=114, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTL8GV06roPeF96gmNNe5qicpI81qEbXLy1oKu8HDafssvuSfccR9UQIFkFFESxJ0ECOjgVoAt6QlaQ/132, createdBy=50201623070, createdName=wylj, createdTime=Sun Sep 17 22:12:32 CST 2017, time=2017-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=245053, encodeId=3fd3245053b0, content=学习了.感谢分享., beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=60791943465, createdName=1e0f8808m18(暂无匿称), createdTime=Sun Sep 17 17:08:59 CST 2017, time=2017-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=245046, encodeId=e7f5245046a2, content=学习了.谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3zSn0GqHrsfLGSUSR8zwnWWLT4FMl5XH8S58HuZslVkLsAPbXDXaliagK7TOxQfmngKibG1yrDonepCLDkcxGk8hS/0, createdBy=b8282062892, createdName=changjiu, createdTime=Sun Sep 17 16:42:01 CST 2017, time=2017-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=245041, encodeId=52c924504147, content=目前仍然C反应蛋白为核心, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=lovetcm, createdTime=Sun Sep 17 15:36:51 CST 2017, time=2017-09-17, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1924723, encodeId=357e1924e2325, content=<a href='/topic/show?id=4fd31388ecf' target=_blank style='color:#2F92EE;'>#PCT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13887, encryptionId=4fd31388ecf, topicName=PCT)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=796422, createdName=lvliquan, createdTime=Fri Oct 06 19:13:00 CST 2017, time=2017-10-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1269594, encodeId=6cce126959415, content=<a href='/topic/show?id=ca6952e52f' target=_blank style='color:#2F92EE;'>#CRP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5275, encryptionId=ca6952e52f, topicName=CRP)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Tue Sep 19 06:13:00 CST 2017, time=2017-09-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=245356, encodeId=5bdf245356e4, content=学习一下新知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=114, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/syBKejEucZo9aZXqKib7wdZYRpZOzeEKDyA59Er4fkK2ff1X7w9pfDTWUY75EBCpsNo0iaGqly7sJMtEPI2Pur6Q/0, createdBy=eb672097339, createdName=lucycici, createdTime=Mon Sep 18 16:43:25 CST 2017, time=2017-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=245341, encodeId=95f42453415d, content=学习.谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyhb9xDeHojCicsdRdyC3XXdGk2ib9yLypZuHN06WeW4HO8WN0GGrgEfvnTX8gsckof05GHOU5OM4Mvx/0, createdBy=9cee1982656, createdName=执着追梦, createdTime=Mon Sep 18 14:17:39 CST 2017, time=2017-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=245192, encodeId=64b7245192a9, content=是, beContent=null, objectType=article, channel=null, level=null, likeNumber=108, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6lR0HdZibhWZ6rWAh3YccOK4EzafUdF0qLoia0v0xMic7vVJosqww22ib6RPRNBMS6ZMP4UvsoiaawAhtW1E5FNJvcK/0, createdBy=ac701981244, createdName=1e182ff9m99(暂无匿称), createdTime=Mon Sep 18 06:31:06 CST 2017, time=2017-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=245150, encodeId=744724515067, content=谢谢分享.感觉收获很大, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160914/IMG57D82E721DB581755.jpg, createdBy=4fc81933929, createdName=明天会更好!, createdTime=Mon Sep 18 00:11:40 CST 2017, time=2017-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=245097, encodeId=a86324509eca, content=谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=114, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTL8GV06roPeF96gmNNe5qicpI81qEbXLy1oKu8HDafssvuSfccR9UQIFkFFESxJ0ECOjgVoAt6QlaQ/132, createdBy=50201623070, createdName=wylj, createdTime=Sun Sep 17 22:12:32 CST 2017, time=2017-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=245053, encodeId=3fd3245053b0, content=学习了.感谢分享., beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=60791943465, createdName=1e0f8808m18(暂无匿称), createdTime=Sun Sep 17 17:08:59 CST 2017, time=2017-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=245046, encodeId=e7f5245046a2, content=学习了.谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3zSn0GqHrsfLGSUSR8zwnWWLT4FMl5XH8S58HuZslVkLsAPbXDXaliagK7TOxQfmngKibG1yrDonepCLDkcxGk8hS/0, createdBy=b8282062892, createdName=changjiu, createdTime=Sun Sep 17 16:42:01 CST 2017, time=2017-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=245041, encodeId=52c924504147, content=目前仍然C反应蛋白为核心, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=lovetcm, createdTime=Sun Sep 17 15:36:51 CST 2017, time=2017-09-17, status=1, ipAttribution=)]
    2017-09-18 明天会更好!

    谢谢分享.感觉收获很大

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=1924723, encodeId=357e1924e2325, content=<a href='/topic/show?id=4fd31388ecf' target=_blank style='color:#2F92EE;'>#PCT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13887, encryptionId=4fd31388ecf, topicName=PCT)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=796422, createdName=lvliquan, createdTime=Fri Oct 06 19:13:00 CST 2017, time=2017-10-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1269594, encodeId=6cce126959415, content=<a href='/topic/show?id=ca6952e52f' target=_blank style='color:#2F92EE;'>#CRP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5275, encryptionId=ca6952e52f, topicName=CRP)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Tue Sep 19 06:13:00 CST 2017, time=2017-09-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=245356, encodeId=5bdf245356e4, content=学习一下新知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=114, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/syBKejEucZo9aZXqKib7wdZYRpZOzeEKDyA59Er4fkK2ff1X7w9pfDTWUY75EBCpsNo0iaGqly7sJMtEPI2Pur6Q/0, createdBy=eb672097339, createdName=lucycici, createdTime=Mon Sep 18 16:43:25 CST 2017, time=2017-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=245341, encodeId=95f42453415d, content=学习.谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyhb9xDeHojCicsdRdyC3XXdGk2ib9yLypZuHN06WeW4HO8WN0GGrgEfvnTX8gsckof05GHOU5OM4Mvx/0, createdBy=9cee1982656, createdName=执着追梦, createdTime=Mon Sep 18 14:17:39 CST 2017, time=2017-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=245192, encodeId=64b7245192a9, content=是, beContent=null, objectType=article, channel=null, level=null, likeNumber=108, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6lR0HdZibhWZ6rWAh3YccOK4EzafUdF0qLoia0v0xMic7vVJosqww22ib6RPRNBMS6ZMP4UvsoiaawAhtW1E5FNJvcK/0, createdBy=ac701981244, createdName=1e182ff9m99(暂无匿称), createdTime=Mon Sep 18 06:31:06 CST 2017, time=2017-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=245150, encodeId=744724515067, content=谢谢分享.感觉收获很大, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160914/IMG57D82E721DB581755.jpg, createdBy=4fc81933929, createdName=明天会更好!, createdTime=Mon Sep 18 00:11:40 CST 2017, time=2017-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=245097, encodeId=a86324509eca, content=谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=114, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTL8GV06roPeF96gmNNe5qicpI81qEbXLy1oKu8HDafssvuSfccR9UQIFkFFESxJ0ECOjgVoAt6QlaQ/132, createdBy=50201623070, createdName=wylj, createdTime=Sun Sep 17 22:12:32 CST 2017, time=2017-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=245053, encodeId=3fd3245053b0, content=学习了.感谢分享., beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=60791943465, createdName=1e0f8808m18(暂无匿称), createdTime=Sun Sep 17 17:08:59 CST 2017, time=2017-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=245046, encodeId=e7f5245046a2, content=学习了.谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3zSn0GqHrsfLGSUSR8zwnWWLT4FMl5XH8S58HuZslVkLsAPbXDXaliagK7TOxQfmngKibG1yrDonepCLDkcxGk8hS/0, createdBy=b8282062892, createdName=changjiu, createdTime=Sun Sep 17 16:42:01 CST 2017, time=2017-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=245041, encodeId=52c924504147, content=目前仍然C反应蛋白为核心, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=lovetcm, createdTime=Sun Sep 17 15:36:51 CST 2017, time=2017-09-17, status=1, ipAttribution=)]
    2017-09-17 wylj

    谢谢分享

    0

  8. [GetPortalCommentsPageByObjectIdResponse(id=1924723, encodeId=357e1924e2325, content=<a href='/topic/show?id=4fd31388ecf' target=_blank style='color:#2F92EE;'>#PCT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13887, encryptionId=4fd31388ecf, topicName=PCT)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=796422, createdName=lvliquan, createdTime=Fri Oct 06 19:13:00 CST 2017, time=2017-10-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1269594, encodeId=6cce126959415, content=<a href='/topic/show?id=ca6952e52f' target=_blank style='color:#2F92EE;'>#CRP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5275, encryptionId=ca6952e52f, topicName=CRP)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Tue Sep 19 06:13:00 CST 2017, time=2017-09-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=245356, encodeId=5bdf245356e4, content=学习一下新知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=114, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/syBKejEucZo9aZXqKib7wdZYRpZOzeEKDyA59Er4fkK2ff1X7w9pfDTWUY75EBCpsNo0iaGqly7sJMtEPI2Pur6Q/0, createdBy=eb672097339, createdName=lucycici, createdTime=Mon Sep 18 16:43:25 CST 2017, time=2017-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=245341, encodeId=95f42453415d, content=学习.谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyhb9xDeHojCicsdRdyC3XXdGk2ib9yLypZuHN06WeW4HO8WN0GGrgEfvnTX8gsckof05GHOU5OM4Mvx/0, createdBy=9cee1982656, createdName=执着追梦, createdTime=Mon Sep 18 14:17:39 CST 2017, time=2017-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=245192, encodeId=64b7245192a9, content=是, beContent=null, objectType=article, channel=null, level=null, likeNumber=108, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6lR0HdZibhWZ6rWAh3YccOK4EzafUdF0qLoia0v0xMic7vVJosqww22ib6RPRNBMS6ZMP4UvsoiaawAhtW1E5FNJvcK/0, createdBy=ac701981244, createdName=1e182ff9m99(暂无匿称), createdTime=Mon Sep 18 06:31:06 CST 2017, time=2017-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=245150, encodeId=744724515067, content=谢谢分享.感觉收获很大, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160914/IMG57D82E721DB581755.jpg, createdBy=4fc81933929, createdName=明天会更好!, createdTime=Mon Sep 18 00:11:40 CST 2017, time=2017-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=245097, encodeId=a86324509eca, content=谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=114, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTL8GV06roPeF96gmNNe5qicpI81qEbXLy1oKu8HDafssvuSfccR9UQIFkFFESxJ0ECOjgVoAt6QlaQ/132, createdBy=50201623070, createdName=wylj, createdTime=Sun Sep 17 22:12:32 CST 2017, time=2017-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=245053, encodeId=3fd3245053b0, content=学习了.感谢分享., beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=60791943465, createdName=1e0f8808m18(暂无匿称), createdTime=Sun Sep 17 17:08:59 CST 2017, time=2017-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=245046, encodeId=e7f5245046a2, content=学习了.谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3zSn0GqHrsfLGSUSR8zwnWWLT4FMl5XH8S58HuZslVkLsAPbXDXaliagK7TOxQfmngKibG1yrDonepCLDkcxGk8hS/0, createdBy=b8282062892, createdName=changjiu, createdTime=Sun Sep 17 16:42:01 CST 2017, time=2017-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=245041, encodeId=52c924504147, content=目前仍然C反应蛋白为核心, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=lovetcm, createdTime=Sun Sep 17 15:36:51 CST 2017, time=2017-09-17, status=1, ipAttribution=)]
    2017-09-17 1e0f8808m18(暂无匿称)

    学习了.感谢分享.

    0

  9. [GetPortalCommentsPageByObjectIdResponse(id=1924723, encodeId=357e1924e2325, content=<a href='/topic/show?id=4fd31388ecf' target=_blank style='color:#2F92EE;'>#PCT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13887, encryptionId=4fd31388ecf, topicName=PCT)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=796422, createdName=lvliquan, createdTime=Fri Oct 06 19:13:00 CST 2017, time=2017-10-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1269594, encodeId=6cce126959415, content=<a href='/topic/show?id=ca6952e52f' target=_blank style='color:#2F92EE;'>#CRP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5275, encryptionId=ca6952e52f, topicName=CRP)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Tue Sep 19 06:13:00 CST 2017, time=2017-09-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=245356, encodeId=5bdf245356e4, content=学习一下新知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=114, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/syBKejEucZo9aZXqKib7wdZYRpZOzeEKDyA59Er4fkK2ff1X7w9pfDTWUY75EBCpsNo0iaGqly7sJMtEPI2Pur6Q/0, createdBy=eb672097339, createdName=lucycici, createdTime=Mon Sep 18 16:43:25 CST 2017, time=2017-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=245341, encodeId=95f42453415d, content=学习.谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyhb9xDeHojCicsdRdyC3XXdGk2ib9yLypZuHN06WeW4HO8WN0GGrgEfvnTX8gsckof05GHOU5OM4Mvx/0, createdBy=9cee1982656, createdName=执着追梦, createdTime=Mon Sep 18 14:17:39 CST 2017, time=2017-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=245192, encodeId=64b7245192a9, content=是, beContent=null, objectType=article, channel=null, level=null, likeNumber=108, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6lR0HdZibhWZ6rWAh3YccOK4EzafUdF0qLoia0v0xMic7vVJosqww22ib6RPRNBMS6ZMP4UvsoiaawAhtW1E5FNJvcK/0, createdBy=ac701981244, createdName=1e182ff9m99(暂无匿称), createdTime=Mon Sep 18 06:31:06 CST 2017, time=2017-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=245150, encodeId=744724515067, content=谢谢分享.感觉收获很大, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160914/IMG57D82E721DB581755.jpg, createdBy=4fc81933929, createdName=明天会更好!, createdTime=Mon Sep 18 00:11:40 CST 2017, time=2017-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=245097, encodeId=a86324509eca, content=谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=114, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTL8GV06roPeF96gmNNe5qicpI81qEbXLy1oKu8HDafssvuSfccR9UQIFkFFESxJ0ECOjgVoAt6QlaQ/132, createdBy=50201623070, createdName=wylj, createdTime=Sun Sep 17 22:12:32 CST 2017, time=2017-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=245053, encodeId=3fd3245053b0, content=学习了.感谢分享., beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=60791943465, createdName=1e0f8808m18(暂无匿称), createdTime=Sun Sep 17 17:08:59 CST 2017, time=2017-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=245046, encodeId=e7f5245046a2, content=学习了.谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3zSn0GqHrsfLGSUSR8zwnWWLT4FMl5XH8S58HuZslVkLsAPbXDXaliagK7TOxQfmngKibG1yrDonepCLDkcxGk8hS/0, createdBy=b8282062892, createdName=changjiu, createdTime=Sun Sep 17 16:42:01 CST 2017, time=2017-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=245041, encodeId=52c924504147, content=目前仍然C反应蛋白为核心, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=lovetcm, createdTime=Sun Sep 17 15:36:51 CST 2017, time=2017-09-17, status=1, ipAttribution=)]
    2017-09-17 changjiu

    学习了.谢谢

    0

  10. [GetPortalCommentsPageByObjectIdResponse(id=1924723, encodeId=357e1924e2325, content=<a href='/topic/show?id=4fd31388ecf' target=_blank style='color:#2F92EE;'>#PCT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13887, encryptionId=4fd31388ecf, topicName=PCT)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=796422, createdName=lvliquan, createdTime=Fri Oct 06 19:13:00 CST 2017, time=2017-10-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1269594, encodeId=6cce126959415, content=<a href='/topic/show?id=ca6952e52f' target=_blank style='color:#2F92EE;'>#CRP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5275, encryptionId=ca6952e52f, topicName=CRP)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Tue Sep 19 06:13:00 CST 2017, time=2017-09-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=245356, encodeId=5bdf245356e4, content=学习一下新知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=114, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/syBKejEucZo9aZXqKib7wdZYRpZOzeEKDyA59Er4fkK2ff1X7w9pfDTWUY75EBCpsNo0iaGqly7sJMtEPI2Pur6Q/0, createdBy=eb672097339, createdName=lucycici, createdTime=Mon Sep 18 16:43:25 CST 2017, time=2017-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=245341, encodeId=95f42453415d, content=学习.谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyhb9xDeHojCicsdRdyC3XXdGk2ib9yLypZuHN06WeW4HO8WN0GGrgEfvnTX8gsckof05GHOU5OM4Mvx/0, createdBy=9cee1982656, createdName=执着追梦, createdTime=Mon Sep 18 14:17:39 CST 2017, time=2017-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=245192, encodeId=64b7245192a9, content=是, beContent=null, objectType=article, channel=null, level=null, likeNumber=108, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6lR0HdZibhWZ6rWAh3YccOK4EzafUdF0qLoia0v0xMic7vVJosqww22ib6RPRNBMS6ZMP4UvsoiaawAhtW1E5FNJvcK/0, createdBy=ac701981244, createdName=1e182ff9m99(暂无匿称), createdTime=Mon Sep 18 06:31:06 CST 2017, time=2017-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=245150, encodeId=744724515067, content=谢谢分享.感觉收获很大, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160914/IMG57D82E721DB581755.jpg, createdBy=4fc81933929, createdName=明天会更好!, createdTime=Mon Sep 18 00:11:40 CST 2017, time=2017-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=245097, encodeId=a86324509eca, content=谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=114, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTL8GV06roPeF96gmNNe5qicpI81qEbXLy1oKu8HDafssvuSfccR9UQIFkFFESxJ0ECOjgVoAt6QlaQ/132, createdBy=50201623070, createdName=wylj, createdTime=Sun Sep 17 22:12:32 CST 2017, time=2017-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=245053, encodeId=3fd3245053b0, content=学习了.感谢分享., beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=60791943465, createdName=1e0f8808m18(暂无匿称), createdTime=Sun Sep 17 17:08:59 CST 2017, time=2017-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=245046, encodeId=e7f5245046a2, content=学习了.谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3zSn0GqHrsfLGSUSR8zwnWWLT4FMl5XH8S58HuZslVkLsAPbXDXaliagK7TOxQfmngKibG1yrDonepCLDkcxGk8hS/0, createdBy=b8282062892, createdName=changjiu, createdTime=Sun Sep 17 16:42:01 CST 2017, time=2017-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=245041, encodeId=52c924504147, content=目前仍然C反应蛋白为核心, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=lovetcm, createdTime=Sun Sep 17 15:36:51 CST 2017, time=2017-09-17, status=1, ipAttribution=)]
    2017-09-17 lovetcm

    目前仍然C反应蛋白为核心

    0

Baidu
map
Baidu
map
Baidu
map